The anxiolytic activity of gabapentin in mice

Journal of Applied Research

Volumn 5, Issue 3, 2005, Pages 415-422

  Sethi, A ^a   Das, B P ^a   Bajaj, B K ^a  

^a BP Koirala Institute of Health Sciences ^*  (Nepal)

Author keywords

Anxiolysis; Experimental model; Gabapentin

Indexed keywords

ANXIOLYTIC AGENT; DIAZEPAM; GABAPENTIN;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG POTENTIATION; ERROR; LEARNING; LOW DRUG DOSE; MALE; MANIA; MEMORY; MEMORY DISORDER; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PASSIVE AVOIDANCE; REARING; STATISTICAL SIGNIFICANCE; TRANQUILIZING ACTIVITY;

EID: 26844578736     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kjernised KD, Bleau P. Long-term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry. 2004;49(suppl 1):51S-65S.
2. Leon A, Portera L, Weissman M. The social costs of anxiety disorders. Br J Psychiatry Suppl. 1997;170:205-208.
3. Kessler R. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Tohen M, ed. Comorbidity in Affective Disorder. New York: Marcel Dekker Inc; 1999:1-25.
4. Ashton H, Young AH. Gaba-ergic drugs: exit stage left, enter stage right. J Psychopharmacol. 2003;17:174-178.
5. Erfurth A, Kammerer C, Grunze H, et al. An open label study of gabapentin in the treatment of acute mania. J Psychiatr Res. 1998;32:261-264.
6. Schaffer B, Schaffer LC. Gabapentin in the treatment of bipolar disorder. Am J Psychiatry. 1997;154:291-291.
7. Letterman L, Markowitz JS. Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacotherapy. 1999;19:565-572.
8. Hatzimanolis J, Lykouras L, Oulis P, Christodoulou GH. Gabapentin as monotherapy in the treatment of acute mania. Eur Neuropsychopharmacol. 1999;9:257-258.
9. Berigan TR. Gabapentin in the treatment of postraumatic stress disorder: a letter to the editor. Prim Care Companion J Clin Psychiatry. 2000;2:105.
10. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155:992-993.
11. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 1998;155:1632.
12. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatr. 1998;43:305.
13. Karam-Hage M, Brower KJ. Gabapentin treatment of insomnia associated with alcohol dependence. Am J Psychiatry. 2000;157:151.
14. Herrmann N, Lanctol K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol. 2000;20:90-93.
15. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. Clin Psychopharmacol. 1999;19:341-348.
16. Weizman R, Raz L, Peter Y, et al. Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm. Brain Res. 2001;901:137-142.
17. De-Paris F, Busnello JV, Vianna MR, et al. The anticonvulsant compound gabapentin possesses anxiolytic but not amnesic effects in rats. Behav Pharmacol. 2000;11:169-173.
18. Watson WP, Robinson E, Little HJ. The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology. 1997;36:1369-1375.
19. Singh L, Field MJ, Ferris P, et al. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl). 1996;127:1-9.
20. Morris GL. Gabapentin. Epilepsia. 1999;40(suppl 5):S63-S70.
21. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacology. 2003;463:3-33.
22. Vohora D, Pal SN, Pillai KK. Effect of locomotor activity on the passive avoidance test for the evaluation of cognitive function. Indian J Pharmacology. 2000;32:242-245.
23. DeVry J. 5-HT1A receptor antagonist: recent developments and controversial issues. Psychopharmacology (Berl). 1995;121:1-26.
24. Straughan JL, Conradie EA. Buspirone-Frontrunner of a new genre of anxiolytics. S Afr Med J. 1998;74:441-444.
25. Rex A, Voigt JP, Voits M, Fink H. Pharmacological evaluation of a modified open field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav. 1998;59:677-683.